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Abstract
This review provides an overview of a remarkable number of significant studies in pediatrics that have been
published over the past year in the Italian Journal of Pediatrics. We have selected information from papers
presented in the Journal that deal with allergy, endocrinology, gastroenterology, genetics, immunology, infectious
diseases, neonatology, nephrology, neurology, pulmonology. The relevant epidemiologic findings, and developments
in prevention, diagnosis and treatment of the last year have been discussed and placed in context. We think that
advances achieved in 2017 will help readers to make the future of patients better.
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Background
A remarkable number of papers that may have a signifi-
cant impact on the management of different childhood
diseases, have been issued in Italian Journal of Pediatrics
in 2017. This review highlights the most accessed arti-
cles and it puts them in the specific context. We have
covered a choice of articles on allergy, endocrinology,
gastroenterology, genetics, immunology, infectious dis-
eases, neonatology, nephrology, neurology, pulmonology
in childhood.
Review
Allergy and immunology
1-diagnosis of cow’s milk allergy; 2 -corticosteroids in
atopic dermatitis; 3-innovative treatments for allergic
diseases; 4-ANCA-associated vasculitis
Clinical features of immediate IgE-mediated reactions
[1] triggered by cow’s milk include skin symptoms (rash,
angioedema, urticaria) [2], nausea, vomiting, abdominal
pain, diarrhea, rhinoconjunctivitis, asthma, anaphylaxis.
The diagnosis of cow’s milk allergy is based on a convin-
cing history and positive IgE tests (skin prick tests
(SPTs) and/or serum specific IgE antibodies [3]), but the
gold standard is a positive oral food challenge [4]). A
systematic review [5] has addressed the utility of SPT or
IgE cut-off values for avoiding cow’s milk challenge. In
children < 2 years of age, an IgE cut-off point of 5 kU/L
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and SPT cut-offs for weal diameter > 6 mm for commer-
cial extract and > 8 mm for fresh milk were found. No
cut-off values were found to predict allergy to fresh
cow’s milk and baked milk in children > 2 years of age.
Cut-off values of IgE tests are affected not only by age
but also by several factors such as studied population,
clinical picture, time of investigation, methods of IgE
testing. So, it is advisable that reliable cut-off values
should be set up by each allergist using data from his
laboratory. Patch test to cow’s milk is not useful [6].
Many efforts have been dedicated to improve the treat-
ment of atopic diseases. The pharmacological first-line
treatment for atopic dermatitis is based on topical corti-
costeroids (TCS) [7], even if a systemic inflammatory
response is often present [8]. Poor adherence and lack of
effectiveness of treatment is commonly caused by steroid
fear [9]. By using a questionnaire, El Hachem M. et al.
[10] investigated “corticophobia” in families of 300 pa-
tients. Eighty-one percent of the respondents reported
to be afraid of TCS. Most care givers were concerned
that danger of TCS was not related to side effect and
that receives help from treatment do not overcome
detriments. There was also fear to incorrectly apply an
excessive quantity of cream. The result of this study
highlights the need for age related educational programs
for the control of atopic dermatitis. Such programs have
been shown to be effective in ameliorating the disease
[11] and in improving the quality of life of eczematous
children [12].
Allergen-specific immunotherapy (AIT) is considered
the only causal disease-modifying treatment for allergic
disorders. Among the 2017 highlights is a consensus
[13] that provides recommendations for use of AIT in
practice. This consensus emphasized that selection of
patients and schedule of administration are a crucial
issue for efficacy of AIT. In children with allergic rhinitis
and allergic asthma, both subcutaneous and sublingual
AIT have very good efficacy and safety. Furthermore, in
children with rhinoconjunctivitis due to grass allergy,
AIT is useful for reducing the risk for asthma develop-
ment. However, it is unclear whether it may reduce the
onset of pollen-food syndrome that is a frequent result
of cross-reactivity between pollen allergens and food
allergens with similar structure [14]. It should be under-
lined that choice of airborne allergens for AIT should be
based on diagnosis of sensitization to relevant genuine
molecules rather than to panallergens [15]. Subcutane-
ous AIT is recommended for allergy to hymenoptera
venom. Oral AIT has shown to be a promising treatment
for IgE-mediated food allergy while there are contrasting
data on the role of AIT in atopic dermatitis [16].
Another area of research has been the treatment of
allergic rhinitis with probiotics. Probiotics may change
immune function by upregulating Th1 pathway and
refurbishing T regs [17]. Moreover, probiotics downregu-
late Th2 cytokines in allergic rhinitis. [18]. Probiotics may
also prevent mucosal damage induced by hydrogen perox-
ide [19] which is increased during exacerbations of
respiratory allergy [20]. Del Giudice et al. [21] showed that
a Bifidobacteria mixture, B longum, B infantis and B breve,
significantly reduced nasal symptom score and improve
quality of life in children with parietaria-induced allergic
rhinitis and was well tolerated. This investigation supports
earlier observations of a possible benefit of adjuvant ther-
apy with probiotics in seasonal allergic rhinitis [22].
Data on anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AVA) are scarce in child-
hood perhaps due to rarity in pediatric age, 0.5–6 new
cases /million children/year, in comparison with adult-
hood, but possibly also due to lack of clinical studies and
investigations on natural history. With this in mind,
Calatroni’s overview of childhood-onset AVA is relevant
[23]. Fever, fatigue, anorexia, and weight loss precede
systemic manifestations. So, early diagnosis is difficult.
In microscopic polyangiitis (MPA), prognosis mainly
depends on renal symptoms that are present in almost
all cases at onset of disease, and on lung manifestations.
Granulomatosis with polyangiitis (GPA, formerly Wege-
ner’s granulomatosis) [24] is characterized by ear, nose
and throat manifestations. Involvement of kidney and
lower respiratory tract is less frequent. Clinical pheno-
types in childhood and adulthood are similar. However,
at variance from adults, children frequently present sub-
glottic stenosis and saddle nose deformity, while periph-
eral neuropathy and cardiovascular involvement are rare.
Eosinophilic granulomatosis with polyangiitis (EGPA,
formerly Churg-Strauss syndrome) usually starts with
asthma, allergic rhinitis, and sinusitis. Later features are
hypereosinophilia with nasal polyps, and lung infiltrates,
and vasculitis with urticarial rash and purpura, and car-
diovascular, musculoskeletal, gastrointestinal, neurologic,
and renal manifestations. ANCA positivity is reported in
50–60% of children with MPA and GPA but only in 25%
of children with EGPA. Children are treated with gluco-
corticosteroids plus cyclophosphamide as with adults
[25]. Rituximab is for non-responsive or relapsing chil-
dren. Other options are mycophenolate, methotrexate,
and plasma exchange. Maintenance treatment includes
azathioprine, low-dose rituximab or mycophenolate.
Mortality rate is 5–10% in children and it is lower than
in adults [26].
Endocrinology
1-obesity; 2-Suclinical hypothyroidism
Pediatric obesity is associated with multiple physical and
psychosocial co-morbidities [27–29] and with premature
morbidity and mortality for metabolic disease and cardio-
vascular events, which are the leading cause of mortality
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in the industrialized countries [30–32]. A few studies ana-
lyzed the presence of cardiometabolic risk factors
(CMRFs) in the very first years of life [33, 34]. CMRFs, in-
cluding fatty liver, were already detectable in preschoolers
with overweight or obesity, despite their short-term
exposure to excess weight [34]. Riaño-Galán et al. [35]
showed higher lipid risk profiles in four-year-old
overweight/obese children, in whom weight status was
also associated to maternal prepregnancy body mass index
(BMI), gestational diabetes, and birth weight. These
findings support the need of prevention actions based on
improving diet quality and increasing physical activity in
women both preconceptionally and during pregnancy.
Additionally, it is recommended identifying children at
risk for obesity as early as possible in the postnatal life and
avoiding excessive weight gain and/or increased
weight-to-length ratio since the very first months of life
[36]. For preventive purposes, it is necessary to rely upon
a classification system with a greater sensitivity in identify-
ing children and adolescents with overweight and obesity.
Valerio et al. [37] compared the ability of different BMI
reference systems in estimating overweight or obesity
children with CMRFs among the BMI references by the
Italian Society for Pediatric Endocrinology and Diabetol-
ogy and those from the World Health Organization
(WHO), and the International Obesity Task Force. WHO
thresholds had the highest sensitivity in identifying obese
subjects with clustered CMRFs. This study arises the
question whether the WHO standards should replace the
national standards for clinical practice and obesity screen-
ing. That is not of secondary importance if we consider
that even a BMI within the accepted normal range, i.e. in
the 50th–74th percentiles during adolescence, was associ-
ated with increased cardiovascular and all-cause mortality
in adulthood [31].
Furthermore, great attention has recently been turned to
severe obesity in children, which affects 4–6% of all youth
in the United States and 2.7% children in Italy [38, 39].
Several studies indeed showed that the prevalence of
CMRFs, psychosocial functioning, bullying experiences and
quality of life rises with greater degrees of obesity [37–40].
All these evidences reinforce the issue that pediatric obes-
ity is a real chronic condition that needs to be effectively
prevented. When obesity is established, there is a need for
early identification and treatment of children who are at
the highest risk of developing the obesity-related complica-
tions. Further studies are necessary to assess whether the
screening for cardiometabolic abnormalities should be
anticipated at an earlier age than is now recommended.
In addition to the obesity-related potentially
life-threatening disease [41–43], over the last decades
increased attention has been focused on the possible causal
relationship between obesity and migraine. Studies in adults
have shown that obese patients are more likely to have
migraine that non-obese individuals and that obesity is
associated to higher frequency and severity of headache
attacks among patients suffering from migraine [44–46].
Comparable results have been reached in children [47–54].
Based on these observations, Verrotti et al. [55] investigated
the impact of a weight loss program on migraine outcome.
Interestingly they found significant improvements in both
adiposity and headache frequency and intensity. Later, the
same cohort of patients was enrolled for a second study
aimed at identifying possible metabolic parameters associ-
ated with good migraine control. Authors reported that not
migraine-free patients showed higher adiposity values and
that insulin resistance status was associated with a 3.5 time
the odds of having persistence of migraine [56].
Despite epidemiologic evidence in both adults and chil-
dren supports the link between obesity and migraine,
causal mechanisms remain poorly understood and specu-
lative. Most likely the linkage between obesity and
migraine is multifactorial and a variety of physiological,
psychological, and behavioral mechanisms have been
proposed. The inappropriate release of hypothalamic
neuropeptides involved in energy balance regulation, as
well as, the systemic pro-inflammatory state produced by
the adipose tissue, might be advocated as possible causal
factors for migraine development in obese individuals.
Different neuropeptides in hypothalamic control of
feeding behavior have been proposed as key players in
migraine pathophysiology. Serotonin through a diverse
array of serotonin receptors impacts feeding behavior and
satiety signaling. Except for transient rises in serotonin
levels during headache attacks, low serotoninergic activity
has been observed in migraine patients. This chronic
decrease in serotonin release could contribute to increase
appetite and weight gain [57–59]. Orexines are hypothal-
amic peptides that regulate arousal, wakefulness, appetite
[60], neuropathic pain, migraine and cluster headache
[61]. Since, low plasma levels of orexin-A have been
detected in obese patients, it has been hypothesized that
this orexin-A deficiency, by promoting the inflammation
in the trigeminal system, might play a role in migraine
genesis. A further neuropeptide is the calcitonin gene
related peptide (CGRP), which is a proinflammatory
substance playing an important role in both induction and
perpetuation of the migraine attack [62, 63]. It has been
observed that obese individuals show elevated levels of
CGRP and that fat intake leads to further increases [64].
Chronically elevated circulating CGRP levels might
decrease the trigemino-vascular activation threshold and
therefore increase or trigger migraine attacks [65].
It is now established that adipose tissue is not only the
primary site of storage of excess energy, but it also serves
as an endocrine organ capable of synthesizing a number
of bioactive substances, the adipokines, that regulate
metabolic homeostasis [66, 67]. Imbalance between
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pro-inflammatory and anti-inflammatory molecules
secreted by adipose tissue may play a critical role in the
development of several obesity-related conditions [68].
Subclinical hypothyroidism (SH), characterized by
serum TSH levels above the upper limit of the reference
range, in presence of normal FT4 concentrations has
distinctive features in childhood [69]. At variance from
adults, in pediatric age SH seems to be less common
(prevalence 1,7%) and is a benign and remitting condition,
with a negligible risk of progression to hypothyroidism.
Wasniewska et al. [70] found that 41.3% of children with
idiopathic and mild SH between 5 and 10 mIU/l [4,
normalized their TSH over time, while 58.7% remained
SH and 12% increased TSH to > 10 mIU/l. None of these
children showed any symptoms of hypothyroidism during
2-year follow-up [71]. Moreover, no alterations in
cognitive functions, growth, bone maturation and body
mass index status were recorded in children with idio-
pathic SH [72, 73].
However, in children with other disorders, including
celiac disease, goiter and elevated anti-thyroglobulin
autoantibodies, there is a deterioration of thyroid status
over time, while in those with no underlying or associ-
ated disorders, there is a spontaneous normalization of
thyroid function. High baseline TSH levels are probably
the most powerful marker of persistent SH over time
[74]. Turner (TS) or Down’s syndrome (DS) are chromo-
somopathies that are known to be linked with an in-
creased risk of autoimmune thyroid diseases (AITDs)
[71]. TS girls with hypothyroidism show a significant
worsening of thyroid function over time and this trend
is irrespective of both karyotype and other factors. DS
children with SH might be prone to exhibit over time a
phenotypic metamorphosis from hypothyroidism to Graves’
disease and to subsequently swing from hypothyroidism to
hyperthyroidism [71].
A biochemical pattern of isolated hyperthyrotropinemia
may be observed in around 7–10% of obese children.
Although the pathophysiological mechanism responsible
for SH in this population is not clear, it is postulated that
the elevated levels of leptin in obese children can affect
the hypothalamic regulation of TSH production. However,
it was found that thyroid function may often normalize
after weight loss. In obese children with longstanding SH,
cardiovascular abnormalities and proatherogenic meta-
bolic alterations may be sporadically seen. The major
determinants of these alterations seem to be the duration
of SH, that may be able to play a direct role on early
atherosclerotic changes, not mediated by either visceral
adiposity or other confounding factors [75]. In children
with idiopathic SH, thyroid function monitoring should
not be performed every 12 months. In HT-related SH
children, thyroid function monitoring should be stricter:
every 6 months. Because the association with either TS or
Ds furtherly impairs the outcome of HT-related SH,
thyroid function monitoring has to be stricter since pro-
gression from SH to overt hypothyroidism is more likely
in these chromosomopathies.
In conclusion, SH is often self-limiting. L-T4 supple-
mentation is not generally recommended in pediatric age,
but it should be taken into consideration only in the cases
with underlying HT or hypothyroid clinical symptoms, or
thyromegaly, or very elevated TSH serum at entry. Recent
studies comparing the effects of treatment versus no
therapy in children with idiopathic SH seem to suggest
that L-T4 therapy is unable to modify post-treatment
outcomes of hyperthyrotropinemia and to prevent the risk
of a further TSH increase after withdrawal [76].
Gastroenterology
1-acute appendicitis; 2-oral mucosal lesions; 3-constipation
The management of acute appendicitis at pre-school age
has been reviewed by Almaramhy et al. [77] who empha-
sized that deferral in diagnosis is frequent because of
vague presenting symptoms and poor communication
skills of children. Several different conditions may be
mimicked including acute gastroenteritis, mesenteric ade-
nitis, intussusception, cholecystitis, constipation, respira-
tory tract and urinary tract infections, nephrolithiasis, hip
arthritis, sepsis, meningoencephalitis. Therefore, young
children are more disposed to develop complications. So,
aiming at the decrease of morbidity and mortality rates
linked to complicated appendicitis, it is required an early
diagnosis. Computed Tomography scan is more useful
than X-ray and ultrasonography. Several scoring systems
may be helpful to reduce exposure to ionizing radiations.
The standard of care for many years has been surgical
appendectomy, but it carries with it several risks, includ-
ing bleeding, wound complications, injury to surrounding
structures, and the latent demand for reoperation.
According to a recent systematic review, initial
non-operative treatment of acute uncomplicated appendi-
citis in children was accompanied by similar rate of com-
plications to children treated with appendectomy [78].
This procedure seems to be able to avoid an appendec-
tomy in 62–81% of the children after one-year follow-up,
although with low evidence. Similarly, a meta-analysis
showed that antibiotics are effective in children with acute
uncomplicated appendicitis without increasing the risk for
complications [79]. The failure rate of antibiotic treatment
is mainly caused by the presence of appendicolith. So,
non-operative management of appendicitis in children can
represent a well tolerated and reasonable treatment choice
in selected patients [80] after discussion with caregivers
on risks and benefits of both surgery and non-operative
management.
Little is known about oral mucosa lesions (OML)
which affects 30% of adolescents [81]. The most
Caffarelli et al. Italian Journal of Pediatrics  (2018) 44:82 Page 4 of 17
common lesions are aphthous ulcers, traumatic ulcera-
tions, herpes simplex virus, geographic tongue, candid-
iasis and morsicatio buccarum. Some types of OMLs
were shown in adolescents with systemic disorders (e.g.
aphthous ulcers and celiac disease), as a consequence
of the disease or as an outcome of the pharmacological
treatment. In particular, multiple oral lesions may be an
early expression of Crohn’s disease in children, preced-
ing also the gastrointestinal manifestations [82]. Usu-
ally, orofacial features associated with Crohn’s disease
are oral ulceration, lip, facial and buccal swelling, mu-
cosal cobblestoning, angular and granulomatous cheili-
tis and gingivitis. Typically, oral lesions may be directly
correlated with the involvement of the mucosa, appear-
ing as granulomas, or may manifest specifically with
stomatitis or aphthous-like ulcers, angular cheilitis, lip
fissuring and gingivitis. Moreover, it must be consid-
ered that the occurrence of oral lesions correlates with
the exacerbations. The paediatric dentists and gastroen-
terologists should be involved in the evaluation and
follow-up of children suffering from Crohn’s disease.
Likewise, OMLs and gingival bleeding may reveal the
evolution of liver failure in paediatric chronic liver diseases
[83]. OMLs, such as candidiasis, telangiectasia, bald tongue,
cracked strawberry lip, yellowish-brown gum discoloration,
petechiae and gingival bleeding were related with the sever-
ity of liver dysfunction, coagulopathy, protein, bilirubin and
creatinine levels and portal hypertension.
Furthermore, OMLs in children and adolescents may
be the expression of malignancy, including mucoepider-
moid carcinomas (22.4%), osteosarcomas (13.8%), squa-
mous cell carcinomas (12.1%), and Burkitt’s lymphomas
(12.1%) [84]. The most commonly affected sites were the
palate (19%), mandible (13.8%), and maxilla (13.8%).
Roughly half the patients were asymptomatic. Due to the
rarity of these malignancies, it is fundamental to develop
a cooperative networking among paediatricians, dentists,
oncologists and surgeons about malignant oral tumours
in children.
Functional constipation is a common gastrointestinal
problem in childhood, rarely due to organic causes,
including structural, endocrine, metabolic or allergic
diseases [85, 86]. The pathogenesis of functional gastro-
intestinal disorders is unclear and probably multifactor-
ial. The laxative treatment of paediatric functional
constipation requires polyethylene glycol (PEG) as first
choice, although it may change the intestinal microflora
accelerating the peristalsis. Therefore, it has recently
raised the interest on the efficacy of probiotics as
supportive treatment for functional constipation. A
probiotic mixture (PM), including Bifidobacteria breve,
infantis and longum has been compared to the therapy
with PEG alone in a paediatric population affected by
FC [87]. In the short term, therapy of children with
chronic functional constipation, PEG and PEG plus PM
were similarly successful and safe. A long-term positive
effect on constipation of the PM may justify further
studies. Similarly, a systematic review found limited
evidence on the effectiveness of probiotics in the
management of constipation in children [88]. Although
specific probiotic strains displayed effects on defecation
frequency, none were useful on faecal incontinence or
abdominal pain. In a randomized trial Lactobacillus casei
rhamnosus Lcr35 was not more effective than placebo in
the management of the FC among children < 5 years [89].
Genetics
1-fragile X syndrome
Fragile X Syndrome (FXS) is the most common known
cause of inherited intellectual disability, diagnosed by
the detection of an alteration of the Fragile X Mental
Retardation-1 gene (FMR1), which maps at the Xq27.3
band, mainly by Triplet primed PCR [90]. FXS presents
typical neurologic/neuropsychiatric features and involve-
ment of multi-systemic characters, such as connective
tissue signs, cardiac defects, gastrointestinal symptoms,
pubertal macroorchidism, ocular anomalies, and obesity.
Because of the physical, emotional and behavioural
implications of the disease, patient management requires
therapeutic strategies and social issues. FXS is associated
with autism spectrum disorder in 50% of males and 20%
of females [91]. This group of patients has a higher
prevalence of seizures, sleep problems in childhood,
increased behaviour complications, and higher use of
α-agonists and antipsychotics. So, there is an urgent
need of early identification of FXS individuals, to start
an appropriate and timely interventions by medical and
social services. A potential strategy to facilitate this pro-
cedure is the large-scale newborn screening [91]. How-
ever, a major limit of the screening may be represented
by the actual lack of an effective targeted treatment
when implemented early in infancy. It is also important
to underline that several mothers, and other family
members of children with FXS may be carriers of a
premutation, less severe in clinical presentation but
associated with different medical, cognitive/developmen-
tal, and psychiatric features [92]. So, an accurate
diagnosis and a better understanding of the natural his-
tory of FXS is needed for better designing treatments,
services and care. Pharmacological treatment is basically
symptom-based to ameliorate behavior problems. Anti-
psychotics and selective serotonin reuptake inhibitors
and lithium are commonly used. Non-pharmacological
therapy including speech-language therapy, behavioral
and physical therapy should be combined. A targeted
therapy is now being studied that may radically change
the destiny of the disease.
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Infectious diseases
1- acute cerebellitis; 2- cytomegalovirus
An eleven-year retrospective multicentric study analysed
clinical, neuroimaging and electrophysiologic features of
acute cerebellitis (AC) and acute cerebellar ataxia (ACA) in
children [93]. A total of 124 children were included, 118
with a diagnosis of ACA and 6 of AC. The most common
signs and symptoms were broad-based gait disturbance,
balance disorders, slurred speech, vomiting, headache and
fever. Neurological sequelae were reported in 6 cases (5%),
frequently associated to pathological magnetic resonance
imaging or computed tomography. These long-term
outcomes usually range from ataxia to mild tremor and the
affected areas of cognition include spatial visualization
ability, language skills, and concentration [94]. Although
most cases are self-limited, these characters suggest
performing an instrumental evaluation in all patients with
AC/ACA at admission with the aim of preventing lethal
complications and identifying patients at higher risk of
neurological outcome [95]. A more aggressive therapeutic
strategy and a closer follow-up should be achieved in this
group of patients.
Cytomegalovirus (CMV) is the most frequent congenital
infection, with a higher incidence in developing countries.
CMV infection, although often asymptomatic at birth,
may cause sensorineural hearing loss and neurodevelop-
mental disabilities in childhood [96]. Infants born to
HIV-infected mothers are at higher risk of acquiring CMV
infection [97]. CMV was positive in 23.2% among infants
with in utero and 9.1% infants with intrapartum HIV
infection recruited in a multi-centre clinical trial.
Moreover, CMV was four-fold more prevalent among
HIV-infected infants compared with uninfected infants
born to HIV-infected mothers not receiving antiretrovirals
during pregnancy. On the contrary, a cross-sectional
Mozambican survey showed no differences in the
prevalence of CMV infection among HIV-exposed and
unexposed neonates [98]. Unfortunately, there is still a
lack of preventive approaches and behavioural procedures
for CMV infection during pregnancy. It is possible to treat
infected infants with a well-tolerated antiviral drug, able
to improve symptoms in childhood but not to eradicate
the long-term sequelae.
Neonatology
1- drug use; 2- neonatal infections; 3-analgesia; 4- care
givers; 5 -vitamin D
In developing countries, neonatal mortality is still high
[99] compared to Western countries, particularly because
of infections [100]. Thus, antibiotics are the most
frequently prescribed medicines, followed by drugs for
respiratory and nervous diseases in neonates, especially if
with a gestational age below 32 weeks and/or birth weight
< 2500 g. Almost 90% of the drugs used in neonatal
intensive care units (NICUs) are off-label or unlicensed
[101] and they are administered intravenously [102]. Gir-
ardi et al. have recently evaluated the drug use in neonates
with low and extremely low birth weight at an Italian
NICU [103]. They found that, compared to neonates with
low birth weight, babies with very low birth weight were
exposed to a higher number of drugs, mainly antibiotics,
antifungals, and diuretics, and received more frequently
associations of potentially nephrotoxic drugs. Moreover,
most of them received more than 10 drugs during their
stay at NICU. For most of these drugs, the risk-benefit
profile is still not fully assessed in the neonatal population,
and scanty evidence is available for their use in combin-
ation. Indeed, at present there is no standard profile of
drug use for neonates in critical care, other than some
efforts towards standardization, such as establishing local
or general guidelines and publications like handbooks and
formularies that are distributed worldwide. Further studies
should explore the safety of the most used drugs in NICU
patients, alone or in combinations, with particular focus
on renal toxicity.
In hospitalized newborns, infections due to Staphylococ-
cus aureus [104] and Candida species have become an
increasingly important problem. In neonatal intensive care
units (NICUs), Candida species are the third most
common pathogen responsible of late-onset infections
and entail high morbidity and mortality rates. Indeed, if
babies survive to the infection, long-term neurological se-
quelae such cerebral palsy, blindness, hearing impairment,
cognitive deficits, and periventricular leukomalacia may
develop [105]. Garzillo et al. have recently investigated the
phenotypic and genotypic features of Candida parapsilosis
microbial isolates and evaluated the underlying clinical
conditions associated with acquisition of the infection in
17 neonates at an Italian NICU [106]. During the 3 years
of the study, Candida parapsilosis was responsible for 6
umbilical catheter- and 11 central catheter-associated
bloodstream infections. Two isolates were resistant to
fluconazole and intermediately susceptible to itraconazole.
Birth weight, gestational age, and length of exposure to
assisted ventilation represented independent risk factors
for Candida parapsilosis infection both at the univariate
and multivariate analysis. The colonization of neonatal
skin and gastrointestinal tract is an important first step in
the pathogenesis of the invasive disease [107]. Future stud-
ies aimed at better understanding the complex interac-
tions between host risk factors and fungal virulence traits
will hopefully allow to reduce the risk of systemic spread
in neonates.
Exposure of newborns to uncontrolled and repetitive
pain is common in neonatal intensive care units (NICUs),
and may affect the infants’ pain perception, cognition,
motor function, and brain development later in infancy.
Therefore, the use of analgesia in neonates has increased
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largely in the last 25 years in order to reduce infants’ stress
hormone response, time to recovery, and mortality rates
[108]. In order to understand how much these practices
have been implemented, the EUROPAIN survey has
prospectively recorded round-the-clock bedside analgesia
practices for all NICU admissions over 9 months. Lago
et al. have recently analyzed the Italian data obtained for
the EUROPAIN survey to document and compare current
analgesia practices at 30 Italian NICUs versus other
European centers and the current national guidelines
[109]. Data from a total of 422 newborns (131 on invasive
ventilation, 150 on non-invasive ventilation, and 141 on
spontaneous ventilation) were collected. Analgesia prac-
tices were documented in the 35.3% of the total and varied
considerably between the Italian NICUs as well as in other
European countries. Strong analgesics, sedatives and mild
analgesics were used in 32.5, 10.2, and 3.8% of the
neonates, respectively. Illness severity, type of ventilation,
and number of NICU beds were factors independently
associated with analgesia use. Only one in four neonates
was treated with boluses alone. The use of analgesia in the
neonatal period is still poorly documented and few studies
on this topic have been published up to now [110].
Further prospective longitudinal studies are warranted in
order to check the performance of analgesia practices and
their adherence to national guidelines.
The NICU environment is dramatically different from
the maternal womb, as the neonate is exposed to varia-
tions in temperature, manipulation, different sensorial
stimuli, noise, light, oxygen, and nutrients. These factors
are a significant source of stress for the newborns and
may negatively influence their neurodevelopmental
outcomes [111]. At present, parents play only a supportive
role in the NICU and thus keep feeling anxious and
unprepared to care for their infant after discharge. On the
other hand, family-centered care (FCC) has been increas-
ingly emphasized as an important and necessary element
in NICUs, as it expands parental presence in the NICU
and requires that they have an active role in their new-
born’s care [112]. De Bernardo and coworkers compared
the satisfaction and stress levels of 48 parents in an FCC
group versus 48 in a non-FCC program at an Italian
NICU over one year [113]. They found not only that
parents in the FCC group were more satisfied and less
stressed than those in the other group, but also that
infants in the FCC group showed a greater increase in
body weight after 60 days. These findings prompt to
support the implementation of FCC in NICUs, and also
demonstrate that parents need to be involved in their
child’s care. As parents play a key role in reducing their
neonate’s stress, caregivers should encourage a greater
parental involvement. Vitamin D insufficiency is common
among children, particularly if born preterm [114] and/or
affected by chronic diseases [115]. Preterm newborns are
at particular risk of vitamin D deficiency as they are
dependent on maternal vitamin D status during pregnancy
and on nutritional intake after birth [116]. At present,
there is still controversy about the adequate daily dose,
duration and type of vitamin D supplementation that
should be administered to preterm neonates. Cho and
colleagues have recently evaluated the efficacy and safety
of early supplementation with 800 IU of vitamin D in 49
very low birth weight infants [117]. They found that 88%
of infants with baseline cord-blood levels of 25 (OH) D ≥
10 ng/mL achieved vitamin D sufficiency at 36 weeks of
postmenstrual age, but the proportion decreased to 65%
in those with baseline cord-blood levels of 25 (OH) D <
10 ng/mL. Only three infants showed laboratory signs of
hypervitaminosis D. These findings confirm and expand
those from previous studies [114] as they demonstrate
that the response to vitamin D supplementation depends
on the baseline vitamin D stores at birth. As Vitamin D is
essential for the normal development of skeletal and
extra-skeletal systems, low 25 (OH) D levels are an issue
for preterm VLBW infants, calling for early nutritional inter-
ventions. Further research is needed to figure out the exact
dose to safely meet target levels without overcorrection.
Nephrology
1- solitary kidney; 2- nephrotic syndrome
During the last decades the potential role of solitary kid-
ney (SK) in promoting systemic hypertension, proteinuria
and glomerulosclerosis has been widely studied. Lubrano
and colleagues [118] assessed mid- and long-term out-
come of children with congenital SK (CSK) or acquired
SK (ASK). Patients with ASK were significantly older than
those in the CSK group [119]. Glomerular filtration rate,
proteinuria, and blood pressure of each patient were col-
lected from medical records at the time of first admission
and at 14 years of age and there was no difference
between groups. Blood pressure values fell into the normal
range for most patients without any difference between
the two groups. At the end of the study period, the
percentage of patient with blood pressure > 90th centile
had significantly increased, A significant increase of prehy-
pertension in the CSK group and a significant increase of
hypertension in the ASK group were found. In the light of
these results, children with SK are potentially predisposed
to a higher risk of hypertension and prehypertension in
later life. Careful monitoring throughout childhood is
therefore mandatory to prevent progression to more ser-
ious complications.
Regarding nephrotic syndrome (NS) in children, this year
has been issued the Consensus on clinical management by
the Italian Society for Paediatric Nephrology [120]. For the
first episode of NS authors recommend a daily glucocortic-
oid therapy with prednisone (PDN) or its active metabolite,
prednisolone at 60 mg/m2/day (maximum: 60 mg/day)
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either in a single daily dose in the morning or in two
divided doses as the efficacy is comparable. A 12-week
treatment regimen including 6 weeks of prednisone at
60 mg/m2 per day plus 6 weeks at 40 mg/m2 (maximum:
40 mg/day) in a single dose on alternate days was recom-
mended. The first relapse requires PDN, 60 mg/m2/day
until urine protein levels normalize for 5 days. The dose is
then reduced to 40 mg/m2 alternate days for 4 weeks.
Sodium restriction to a level < 1–2 g or < 35 mg/kg daily
and fluid restriction is recommended in case of mild
oedema. Moderate oedema may require loop diuretics in
addition to salt and water restriction. In case of severe/re-
fractory oedema unresponsive to oral or i.v. loop diuretics a
thiazide diuretic and albumin infusions should be adminis-
tered. The complications of childhood NS are associated
with disease activity and therapy. Infections are a common
complication but there are no data supporting the efficacy
of prophylactic antibiotic therapy. Thromboembolism
develops in 2 to 5% children with NS. A thrombophilia
screening is recommended only in patients with risk factors
for thromboembolism such as known abnormalities of
pro-thrombotic coagulation factors or a family history of
thrombotic events at a young age (< 50 years). Prophylactic
anticoagulation/antiplatelet should be considered in the
setting of concomitant cardiovascular abnormalities,
thromboembolism history, an underlying hypercoagulable
condition beyond NS, steroid-resistant NS, and the
presence of a central venous catheter. Prophylactic proton
pump inhibitors (PPIs) during steroid therapy is necessary
only in patients with gastric symptoms or with other risk
factors for gastrotoxicity. At the time of first presentation,
15–20% of children with NS fail to achieve complete
remission within 4 weeks of corticosteroid therapy and are
classified as having steroid-resistant nephrotic syndrome
(SRNS). These children are at increased risk for progression
to end-stage kidney disease. Because of this risk and the po-
tential utility of histology for therapeutic decision-making,
kidney biopsy should be performed. The most common
finding on kidney biopsy in patients with SRNS is a focal
segmental glomerulosclerosis (FSGS). Although a definitive
pathogenic mechanism has not been identified it seems that
some forms of FSGS may be due to genetic mutations of
podocyte proteins [121]. Five particular gene mutations are
involved in nonsyndromic FSGS, each of these genes play a
role in the development, migration, basement membrane
interaction, and regeneration of the podocyte. It is also
possible that a circulating serum factor may cause SRNS.
Accordingly, proteinuria develops immediately after renal
transplantation in patients with FSGS. Dogra and colleagues
[121] suggested the need for genetic testing in a patient with
NS, aged less than 2 years with positive family history of
nephrotic syndrome, consanguinity, a steroid-resistant
course, and histopathologic findings of FSGS or diffuse
mesangial sclerosis on renal biopsy.
Therapy for SRNS includes immunosuppressive, immu-
nostimulatory and non-immunosuppressive drugs. The
more commonly used immunosuppressive drugs are
calcineurin inhibitors, mycophenolate mofetil (MMF),
pulse intravenous methylprednisolone, and cytotoxic
agents. In a randomized controlled trial, Sinha et al. [122]
showed that in children with idiopathic SRNS 61% of
patients achieved complete remission and 38% partial
remission after treatment with tacrolimus for 6 months.
Then, children were randomized to receive tacrolimus or
MMF both associated to prednisolone on alternate days
for 12 months. At the end of 12 months follow-up, rate of
patients with a complete and partial remission was signifi-
cantly higher in tacrolimus group (90.3%) compared with
MMF group (44.8%). Children treated with MMF had a
significant higher incidence of relapses and they needed a
significant higher dose of prednisolone. Rituximab, a
monoclonal antibody directed against the cell surface anti-
gen CD20 expressed on B lymphocytes, has been used in
children with idiopathic NS resistant to steroids and to all
immunosuppressive agents (approximately 1–3% of cases).
However, there are promising data but no clear evidence
that rituximab is effective for patients with refractory
SRNS [123]. In patients with complicated frequently
relapsing/steroid-dependent NS, rituximab does not cure
the renal disease, as most patients relapsed during
follow-up and need to continue immunosuppressive
agents (such as CsA or MMF) after rituximab treatment
to get long-term remission [124]. Moreover, rituximab
increases the risk of infection, mostly viral, because of
B-cell depletion [125]. Fujinaga and colleagues [126]
reported complete remission after repeated administration
of Rituximab in a child with refractory SRNS due to FSGS.
Two months after the last administration of Rituximab
the patient developed severe hypogammaglobulinemia
requiring i.v. gammaglobulin. Novel agents are under
investigation, but their safety and efficacy have not yet
been determined.
Neurology
1-sleep habits; 2-Ataxia; 3-child abuse and neglect; 4- Fabry
disease; 5- congenital myopathies
Several researches have demonstrated that non-sufficient
sleep in childhood is associated with immediate and
long-term adverse consequences for mental and physical
health. A questionnaire study investigated sleep habits of a
large cohort of Italian children between 1 and 14 years to
assess their relationship with evening activities performed
before bed time [127]. Younger children slept longer than
the older ones. The mean sleep duration was 11.5 h in 1
to 3 years old children vs 9.0 h in 10 to 14 years old but
only 66.9% of them got sufficient sleep as recommended
by National Sleep Foundation [128]. The use of display
devices before sleeping was a significant predictors of
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shorter sleep duration. Similarly, having TV in the
bedroom, being only child, bottle use habit and a history
of sleep disorders during the first year of life negatively
influenced optimal sleep conditions. These data agree with
the literature data worldwide of the last decade. Tamura
and colleagues [129] found a higher incidence of insomnia
and depression and a shorter sleep duration in adolescent
using mobile phone for 5 h or more per day. Females had
a longer use of mobile phone than males. In particular,
hours spent using a mobile phone for social networking
sites and online chat were linked with depression, while
internet searching and playing video games were not.
In 2334 Canadian children [130] a longer sleep duration
was associated with frequent reading a book in the
bedroom and absence of electronic devices, on the con-
trary use an electronic device before to sleep was associ-
ated with shorter sleep duration and shorter total time in
bed. Children with a frequent use of computer and TV
during the hour before sleep had 20% odds of being over-
weight and double odds of being obese. Results were simi-
lar for cell phones use. Surprisingly, children having a TV
or a video game in their bedroom were at risk of over-
weight and obesity even if they did not use them before
sleeping. A study conducted in USA among low-income
preschoolers found an inverse relationship between sleep
duration and body mass index (BMI) [131]. Future studies
investigating the association between sleep duration,
electronic devices use, and BMI are needed to clarify this
relationship and the risk of overweight and obesity par-
ticularly in high-risk population.
Ataxia is a manifestation of a multitude of disease
processes, and an underlying etiology needs to be investi-
gated. Detecting ataxia can be challenging specially in
early childhood but simple signs and maneuvers can help
to recognize ataxia. In a recent review, Pavone and
colleagues [132] provided a general approach to assessing
and managing the patient with ataxia, they also reported
the background and common etiologies of ataxia.
Unsteadiness of gait with loss of balance is the more
common symptom in younger children. Older children
often feel insecure and have to hold onto the wall and
walk with feet apart. In children over 3 years typical
maneuvers such as finger to finger or finger to nose, and
rapid alternating hand movements can be performed to
explore coordination, while dysmetria can be tested
through heel-knee test. Children with ataxia tend to fall
down with closed eyes (Romberg sign positive) and cannot
hold a glass of water without letting the water fall from
the glass. They suggest different ways to classify ataxias
but conclude that, in children, the most useful considers
time trend. Ataxia may be distinguished as being acute,
intermittent and recurrent, chronic-non-progressive and
chronic-progressive. The most common etiologies of
acute ataxia in children are excessive drug ingestion, drug
intoxications and post-infectious cerebellitis, while basilar
migraine is the most common cause of intermittent ataxia.
But ataxia can also be a sign of rare and more complex
diseases as hereditary ataxias. The most well-known of the
inherited ataxias includes ataxia-telangiectasia (AT), a
rare, neurodegenerative, multiorgan, autosomal recessive
disorder causing severe disability. Because of his rarity, the
diagnosis of AT is often delayed but it can be made earlier
with serum alpha feto-protein (AFP) measurement, a
readily available and inexpensive test for all toddlers and
children with undiagnosed chronic or progressive ataxia
[133]. Children with AT suffer from increased mortality
because of lymphoreticular malignancy, infections of the
respiratory system, and various complications. The gene
mutated in AT, ATM (ataxia telangiectasia mutated) gene,
encodes a large protein kinase. The nature of the immune
deficiency is highly variable due to a plethora of mutations
of the ATM gene. Some children have a variant AT in
which a residual kinase activity leading a milder clinical
phenotype, with different immunoglobulin patterns and a
longer survival compared to classical AT patients. Life
expectancy seems to correlate to some immunoglobulin
pattern alterations (IgG2 deficiency or hyper IgM pheno-
type with hypogammaglobulinemia) [134].
In recent decades, the concept of child abuse and neglect
has evolved [135]. Children of the new era are increasingly
stressed because of changes in living conditions, modern
family types, loss of a parent or increasing expectations
from parents, teachers or other family members. Increas-
ingly large numbers of children and adolescents have been
forced to migrate across the world for several reasons.
Mental health of these children is of particular concern
because of their experiences. The exposure to organized
violence and threats arising from religious, cultural, and
political differences, or territorial disputes make them
vulnerable to several and cumulative risks to their physical,
emotional, and social development. Another class at risk
are children in long-term foster care. Several evidences
show that children in care have significant developmental,
behavioral, and emotional problems. Parental divorce/sep-
aration is among the most commonly endorsed adverse
childhood events and is another highly prevalent risk factor
associated with high rates of mental health problems for
youth and increased later risk of alcohol dependence across
adolescence and early adulthood [136].
Soares and colleagues [137] conducted a comparative
study to examine the association between parental divorce
during childhood and cardiometabolic risk factors in youth,
using data from 2 cohort studies in contrasting contexts
(the United Kingdom and Brazil). In both cohorts, cigarette
daily smoking was more frequent among adolescents whose
parents separated before age 18 years. There was no inter-
action between age at parental separation and parental rela-
tionship conflict and cardiometabolic risk factors. A higher
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risk of harmful alcohol use was seen in Brazilian cohort but
not in English one. Several studies of child maltreatment
and sexual risk behavior have shown that males and females
who experienced any kind of sexual abuse had significantly
increased odds of engagement in risky sexual behaviors, but
a recent study revealed that other forms of maltreatment
can increase risky behaviors. Thompson and colleagues
[138] showed that maltreated youths continue to be at high
risk for engaging in behaviors that may start a trajectory of
problematic sexual behaviors. Clinical and prevention pro-
grams should target adolescents with a history of maltreat-
ment and pediatric clinicians have a responsibility to screen
at-risk youth for maltreatment experiences. A recent review
[139] focused on possible means to screen for child
physical, sexual, and psychological abuse and neglect. One
screening tools for physical abuse, called the “Escape Form”
was applicable to children of any age. Limit of this tool is
the use only in emergency situations. Only one screening
instrument was found for sexual abuse but it was not ap-
proved by the International Association of Forensic Nurses
and no screening tool was found to identify psychological
abuse and neglect in children. These findings show that fur-
ther efforts are needed to develop an effective instrument
that can identify and prevent child maltreatment and im-
proving child welfare services.
Fabry Disease (FD) is an X-linked multisystemic,
lysosomal storage disorder caused by deficiency of
α-galactosidase A activity, with consequent accumulation
of globotriaosylceramide (Gb3) and related glycosphingoli-
pids, such as globotriaosylsphingosine (lyso-Gb3) in lyso-
somes. The main complications of FD are more prominent
after the age of 30 when kidney, heart and/or cerebrovascu-
lar disorders appear. Regarding cardiac involvement, de-
posits of neutral glycosphingolipids within cardiocytes lead
to myocyte hypertrophy and fibrosis causing conduction
abnormalities, left ventricular hypertrophy (LVH) or valvu-
lar fibrosis. Patients with manifestations limited to the heart
have been reported as a disease variation. Csányi et al. [140]
have found a novel Ile239Met mutation in α-galactosidase
A gene in a family with a predominant cardiac phenotype
of Fabry disease. In this family, 6 individuals carried the
Ile239Met mutation of whom 3 members manifested the
cardiac phenotype of hypertrophic cardiomyopathy and 2
other family members showed LVH. Interestingly, 4 of the
5 with cardiac involvement were female individuals. This
finding is unusual for cardiac FD since the disease shows X
linked inheritance.
Wilson et al. [141] analyzed electrocardiographic and
clinical findings in pediatric FD patients. The most
common arrhythmia was sinus bradycardia (23%), followed
by ectopic atrial rhythm (12%) and premature atrial
contraction (8%). No episodes of nonsustained ventricular
tachycardia, supra ventricular or ventricular tachycardia,
atrial fibrillation and no PR or QTc intervals abnormalities
were found. Only 1 female developed a first-degree
atrioventricular block during follow-up. Chest pain (35%)
and palpitations (23%) were the most common symptoms.
Echocardiography detected aortic root dilation in 3 pa-
tients, one of them also had concurrent mild aortic insuffi-
ciency. These findings show that cardiological involvement
in Fabry disease at the beginning is limited and this results
in clinical symptoms, abnormalities of conduction and
structure largely heterogeneous. In cardiac involvement in
a Fabry’s patient, enzyme replacement therapy (ERT)
should be started before myocardial fibrosis has developed
to achieve long term improvement. Many efforts are
needed in order to identify early cardiac alterations to
increases the chances of patients to receive a proper ther-
apy and suggest the best age for ERT onset. A recent study
suggests that blood LysoGb3 concentrations measurement
could aid to define a threshold concentration for new pre-
ventive and therapeutic approaches [142].
After the diagnosis of FD in a 11 years old child, the
authors detected the same disease in his little brother,
14 years younger, during neonatal period. The younger
brother underwent LysoGb3 analysis at 2 days of life.
Blood LysoGb3 concentration obtained from the asymp-
tomatic second-born were compared with serum levels
from the symptomatic first-born: there was a 5-fold
increase from the neonatal period to childhood; more-
over, at five months of age the concentration of LysoGb3
reached 40% of the value observed in the symptomatic
phase moreover. They also noted that during neonatal
period the value was 15 times higher than children
without FD. These findings have demonstrated the key
role of LysoGb3 as potential mean to diagnose FD. The
authors documented an early plateau during infancy
which precedes the symptomatic phase. This can help to
identifying a metabolic threshold may lead to new pre-
ventive and therapeutic approaches.
First specific therapy for Fabry’s disease is enzyme
replacement with recombinant human galactosidase A
that provides an exogenous source of deficient enzyme
in patients with this progressive disorder. Two drugs are
now commercially available: agalsidase alpha and agalsi-
dase beta. A global shortage of agalsidase-β between
2009 and 2012 caused many patients worldwide to be
switched from agalsidase-β to agalsidase-α. Skrunes and
colleagues [143] described the effects of switch from
agalsidase-β 1.0 mg/kg/every other week (eow) to
agalsidase-α 0.2 mg/kg/eow in serial kidney biopsies in 3
patients. Each patient was reassessed by renal biopsy
after 5 years of agalsidase-β and 3 years of agalsidase-α.
Biopsies after 5 years of agalsidase-β 1.0 mg/kg/eow
showed marked clearing of globotriaosylceramide (GL3)
from mesangial and endothelial cells and partly cleared
podocytes in all patients. After 3 years of agalsidase-α on
a lower dose (0.2 mg/kg/eow) there was a reaccumulation
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of GL3 in podocytes, but not in the mesangium or
endothelium. When agalsidase-β was again globally avail-
able, one of the patients was reswitched to agalsidase-β
with a consequent decrease of podocyte GL3 deposits.
These results point out the importance of dose in enzyme
replacement therapy (ERT) in preventing irreversible
kidney damage.
Congenital myopathies (CM) are a heterogeneous group
of muscular disorders characterized by the presence of
specific morphologic features on skeletal muscle biopsy.
More than 25 genetic causes of CM and several types of
mutations within the same gene have been found. Cassan-
drini et al. [144] focused on clinical and genetic forms of
CM in order to facilitate histological and imaging diagno-
sis. Based on the results of muscle biopsy can be recog-
nized five forms of CMs: nemaline myopathy (NM), core
myopathy, centronuclear myopathy, congenital fiber-type
disproportion myopathy, myosin storage myopathy. The
morphological hallmark of NM is the presence of nema-
line bodies or rods. It is usually considered the most usual
form of congenital myopathy, although central core
disease can have higher prevalence due to longer term
survival. Rod bodies may be present in most muscle fibers,
and may occupy over half of a fiber’s volume. In a rare
subtype of NM nemaline bodies are present inside
myonuclei. There are currently ten known genetic causes
of NM, of which the nebulin (NEB) gene, inherited in an
autosomal recessive manner, and actin (ACTA1) gene
inherited in an autosomal dominant (90%) or recessive
(10%) way, are the most important. Core myopathy is an
autosomally inherited muscle disorder characterized by
the presence of cores in muscle fibers, they can be single
or multiple in the same muscle fiber. The disease is associ-
ated with defects in the RYR1 gene located on the
chromosomal region 19q12–13.2. There are some families
in which no abnormality has been found in the RYR1
gene, thus suggesting that mutations in other unidentified
genes may be responsible in a minority of families. The
other forms of CM are relatively rare. Identification of the
true gene mutation is indispensable for a better clinical
stratification. However, it is difficult establishing a correct
genetic diagnosis for CM. New clinical and histological
phenotypes are still being identified for some of the
known disease genes and this for many reasons. Further-
more, mutations in different genes can cause many of the
histological patterns, and mutations in a single gene can
result in various histopathological abnormalities. New
genetic approaches are being devised, such as full genome
sequencing, which are likely to overcome this barrier and
allow even the rarest genetic disorders to be genetically
characterized.
As seen, the most important diagnostic clues of con-
genital myopathies are the presence of particular abnor-
malities of muscle fiber architecture on muscle biopsy.
Witting et al. [145] reported a comprehensive analysis of
the prevalence, genotype, and phenotype of CM in
patients 5 years and older in Denmark. After identifying
all registered Danish patients with a diagnosis of CM
aged older than 5 years, comprehensive clinical, histo-
pathologic, and genetic investigations were performed.
Of 82 patients included in the study, 41 had specific
histology. A core myopathy was detected in 14 (17%), a
centronuclear myopathy (CNM) in 15 (18%), and nema-
line myopathy (NM) in 12 (15%). The other patients had
undistinctive features on biopsy. A genetic etiology was
reached for 83% of patients with histopathologic features
of core myopathy CNM, or NM but only for 29% of
patients with unspecific histopathologic features (56% of
overall cases). The authors also found that the preva-
lence of CM in Danish patients older than 5 years was
2:100,000 significantly lower than previous studies. This
may be due to the exclusion of pediatric patients who
have succumbed to their illness prior to age 5. This
approach allowed for a unique prospective assessment of
this patient group that has not been studied previously
in CM.
Congenital NM due to mutations in troponin T1
(TNNT1) has hitherto only been described as a result of a
single homozygous nonsense founder mutation in patients
of Amish origin and in other individuals with 4 different
recessive mutations. Konersman and colleagues [146]
described a novel heterozygous missense mutation of
TNNT1 responsible of NM. Blood samples from members
of an extended family with Ashkenazi Jewish ancestry
underwent Sanger sequencing for TNNT1. The history of
the family revealed multiple cases of myopathy in three
different generations and a mild phenotype with consider-
able clinical heterogeneity. Skeletal muscle biopsies
showed severe type 1 fiber hypotrophy, with many red/
purple-staining rod-like structures exclusively in type 1
fibers. Genetic testing showed the presence of a novel
heterozygous missense variants in exon 9 of the gene
TNNT1 c.311A > T. This mutation was transmitted in an
autosomal dominant fashion whilst, all of the previously
described mutations were autosomal recessive cases of
TNNT1-related NEM. This report expands the phenotype
associated with TNNT1 mutations and may lead clinicians
to suspect NEM5 outside the Amish population particu-
larly in mild cases of NM with nemaline rods and an auto-
somal dominant pattern of inheritance.
Pulmonology
1-oral corticosteroid; 2-prevention of bronchiolitis
Acute respiratory diseases are still a leading cause of child-
hood morbidity and mortality. Both inhaled and systemic
corticosteroids have been widely used for the treatment of
many acute respiratory illnesses associated with airway
inflammation. Recently, Cutrera et al. [147] have reviewed
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the role of oral corticosteroids in the treatment and
management of pediatric bronchiolitis, wheezing, asthma,
and croup. Bronchiolitis is the most common cause of
acute lower respiratory infection in the first year of life,
with the highest rate of hospitalization occurring in
infants aged less than 3 months, preterm babies, children
with chronic lung, heart or neuromuscular diseases, and
infants with immunodeficiency. Moreover, bronchiolitis
due to respiratory syncytial virus, particularly if severe,
increases the risk of recurrent wheezing and asthma later
in life. Oxygen supplementation and hydration remain the
mainstay of treatment, while there is no evidence support-
ing the usefulness of inhaled or oral corticosteroids in
routine practice, as they do not decrease the incidence or
duration of hospitalization, neither do they improve the
short- and long-term prognosis. Preschool wheezing is a
heterogeneous condition that usually resolves by school
age but may also represent the first manifestation of
asthma in some children. Therapeutic strategies for recur-
rent wheezing are tailored to the frequency and severity of
clinical manifestations [148]. Evidences supporting early
family/carer-initiated oral corticosteroids for home
management of exacerbations are weak, and moreover
this treatment is not indicated for preschool children with
mild exacerbation of viral wheeze, while it should be
reserved to patients with severe wheezing exacerbations.
Asthma is one of the most common reasons for urgent
care, emergency department visits and hospitalizations.
The primary goal of asthma management is to achieve
disease control, as asthma not responding to treatment
may result in significant morbidity, including risk of future
exacerbations and progressive loss of lung function [149].
Oral corticosteroids are commonly used in case of moder-
ate and severe asthma attacks [150], since they result in
fewer and shorter hospitalizations, more rapid improve-
ment in lung function, lower rate of relapse after discharge
from the emergency department, and reduced need for
SABA. A liquid formulation should be preferred to tablet
in children. Laryngotracheitis, or viral croup, is often mild
and self-limiting, and usually resolves without any active
intervention. Oral corticosteroids are the treatment of
choice for children with mild-to-moderate croup, while
inhaled corticosteroids and nebulized epinephrine are
indicated for children with severe respiratory distress. One
of the most frequent medical problems affecting newborns
and infants is the occurrence of respiratory infections
[151]. Worldwide, bronchiolitis is the main cause of lower
respiratory infection in infants. Several studies have
investigated the relationship between breastfeeding and
bronchiolitis. The advantages of breastfeeding are largely
documented across different health outcomes in both
developed and low-income countries. In particular, the
positive effects of breastfeeding seem to be clear in redu-
cing the risk of infectious diseases in infants. During the
transitional period from prenatal to postnatal existence,
newborns are highly susceptible to infections because of
their immunological immaturity. After the fetus has
developed in the sterile protective environment within the
uterine cavity, at birth the immune system undergoes a
maturation process that is modulated by exposure to a
variety of maternal and environmental infectious and
non-infectious agents. Among them, many anti-microbial,
anti-inflammatory and immunomodulatory agents present
in human milk stimulate the maturation of the immune
system conferring an overall protection to the newborn. It
has been widely discussed that breastfeeding protects
infants against respiratory infectious diseases, however the
results of the studies conducted so far are controversial.
Indeed, the composition of breast milk significantly affects
children’s immune function and development by
providing several soluble factors. Li et al. [152] assessed
the concentrations of some immunomodulatory constitu-
ents of human milk from mothers of 20 infants with
bronchiolitis and 11 healthy controls. They found that
breast milk IgG levels were significantly lower in mothers
of bronchiolitis patients than in those of controls, while
there were no significant differences in total T, B, or NK
cells between the two groups. Indeed, it has been
previously published that infants receiving exclusively or
non-exclusively maternal milk have an overall lower risk
of bronchiolitis occurrence, with similar levels of protec-
tion for both groups [153]. Taken together, these results
may be explained by the wide properties of maternal milk,
that has both a direct and an indirect action against
pathogenic agents. IgG contained in breast milk may be
absorbed by the breastfed infant and modulate his/her
immune responses, which could play a significant role in
the resistance against bronchiolitis.
Bronchiolitis is one of the most relevant health burdens
in infants and young children worldwide. Respiratory syn-
cytial virus (RSV) is the most frequent pathogen involved,
with about 34 million new cases in children younger than
5 years, 3.4 million admissions to hospitals, and about
199,000 deaths per year, predominantly in the developing
world [154]. In 1998, the monoclonal antibody palivizu-
mab was approved for the prevention of severe RSV infec-
tion in infants with bronchopulmonary dysplasia and in
children born at ≤35 weeks of gestational age. Subse-
quently, Italian Guidelines recommended palivizumab
prophylaxis also for infants born at 29–35 weeks of
gestational age and a chronological age ≤ 6 months at the
beginning of the epidemic season, in presence of risk con-
ditions predisposing to severe infections and/or need for
hospitalization, such as attendance of the child in a com-
munity setting and/or presence of one or more cohabitees
younger than 5 years. However, in 2014 the American
Academy of Pediatrics recommended against the use of
RSV prophylaxis in all children born at 29–35 weeks
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unless the infant has an underlying health condition such
as bronchopulmonary dysplasia or congenital heart
disease. Following these changes, in September 2016 the
Italian Drug Agency decided for the total financial cover-
age of the palivizumab prescription to healthy preterms
only if they were < 29 weeks of gestational age at birth and
if are aged ≤12 months at the beginning of the RSV epi-
demic season. Capizzi et al. evaluated the possible impact
on the incidence and severity of RSV bronchiolitis after
the new prescription limitation [155]. They found that,
compared to the 2 years before the changes made by the
Italian Drug Agency, during the year after the prescription
limitation start there was a significantly higher proportion
of admissions to hospital for RSV bronchiolitis in infants
< 36 weeks of gestational age at birth and of patients
needing high flow nasal cannula ventilation. These find-
ings have been recently confirmed by an American study,
showing that RSV hospitalization rates increased by
2.7-fold in infants aged 29–34 weeks of gestational age at
birth [156]. Taken all together, these results are of clinical
concern and point towards the need for a re-evaluation of
the role of palivizumab prophylaxis in infants aged >
29 weeks of gestational age at birth.
Conclusion
The year 2016 has been an exciting year in many areas
of pediatrics. The Italian Journal of Pediatrics is not
devoted to a single pediatric specialty and new data
could also be found in other journals. However, the 2017
content has provided a great quantity of clinically useful
information that improve our understanding in many
fields. Basic studies have analyzed steps toward reducing
neonatal mortality in developing countries and improv-
ing sleep habits. Indications on risk factors for Candida
parapsilosis, migraine and hypothyroidism have been
reported. Progresses in our understanding of bronchio-
litis have highlighted the role of human breast milk and
of palivizumab in prevention of RSV infection. Novel
observation on assessment of SPTs for the identification
of children with cow’s milk allergy, definition of obesity
and differentiation of OML have been presented to
facilitate diagnosis. Consensus on AIT and on manage-
ment of nephrotic syndrome are an important support
to improve quality of care. Recent advances have also
included many observations that can contribute to a
better approach to diagnosis and treatment of children
with acute appendicitis, ANCA-associated vasculitis,
ataxia, FXS, congenital CMV infection, CM, FD and
hypertension in SK. Insights have emerged on etiopatho-
genic mechanisms and clinical aspects of less frequent
illnesses such as acute cerebellitis and SSSS in newborns
that improve the current management. Progresses have
emphasized a need to better support caretakers for pre-
venting abuse and backing parents of infants admitted at
NICU. Important advances in treatments have included
drug use among preterm neonates, sedation and anal-
gesia in NICU, Vitamin D supplementation, TCS phobia
and benefits from probiotics in allergic rhinitis and
chronic functional constipation. We hope this review
would be useful to give guidance to at once ameliorate
patient care.
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